These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 681807)

  • 1. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C; Grady RW; Cerami A
    J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG; Gupta G; Estes WE; Rosenkrantz H; Metterville JJ; Crumbliss AL; Palmer RA; Nordquest KW; Hardy KA; Whitcomb DR; Byers BR; Arceneaux JE; Gaines CG; Sciortino CV
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ
    Exp Hematol; 1986 Nov; 14(10):971-4. PubMed ID: 3770104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats.
    Hershko C
    Blood; 1978 Mar; 51(3):415-23. PubMed ID: 623907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C; Grady RW; Link G
    Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron retention and excretion in mice transfused with homologous or heterologous blood and treated with chelators.
    Gralla EJ; Burgess DH
    Methods Find Exp Clin Pharmacol; 1982; 4(3):151-9. PubMed ID: 7121126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concepts and goals in the management of transfusional iron overload.
    Porter JB
    Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
    Rivkin G; Link G; Simhon E; Cyjon RL; Klein JY; Hershko C
    Blood; 1997 Nov; 90(10):4180-7. PubMed ID: 9354689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced biliary iron excretion with amphiphilic diethylenetriaminepentaacetic acid.
    Adams PC; Lin E; Barber KR; Grant CW
    Hepatology; 1991 Dec; 14(6):1230-4. PubMed ID: 1959873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH; Cerny EA; Wright BJ; Rahman YE
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of new iron-chelating drugs. II.
    Grady RW; Graziano JH; White GP; Jacobs A; Cerami A
    J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the chelating agent diethylenetriaminepentaacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stores.
    Hershko C
    J Lab Clin Med; 1975 Jun; 85(6):913-21. PubMed ID: 1138024
    [No Abstract]   [Full Text] [Related]  

  • 19. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
    Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
    Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.